Cargando…

Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review

BACKGROUND: To evaluate the objective clinical outcomes of active specific immunotherapy (ASI) in advanced colorectal cancer (advanced CRC) and suspected minimal residual colorectal cancer (suspected minimal residual CRC). METHODS: A search was conducted on Medline and Pub Med from January 1998 to J...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rao, Benqiang, Han, Minyan, Wang, Lei, Gao, Xiaoyan, Huang, Jun, Huang, Meijin, Liu, Huanliang, Wang, Jianping
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041676/ https://www.ncbi.nlm.nih.gov/pubmed/21272332 http://dx.doi.org/10.1186/1479-5876-9-17

Ejemplares similares

Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals
por: Wang, Xiaoxue, et al.
Publicado: (2017)

Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals
por: Wang, Xiaoxue, et al.
Publicado: (2022)

PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d
por: Huang, Lanlan, et al.
Publicado: (2018)

Advances in immunotherapy for colorectal cancer: a review
por: Golshani, Gol, et al.
Publicado: (2020)

Circulating Tumor DNA Response and Minimal Residual Disease Assessment in DNA Polymerase Epsilon-Mutated Colorectal Cancer Undergoing Immunotherapy
por: Lutfi, Areeb, et al.
Publicado: (2023)

Immunotherapy for Colorectal Cancer
por: Boland, Patrick M., et al.
Publicado: (2017)

Minimal Residual Disease in Colorectal Cancer: Are We Finding the Needle in a Haystack?
por: Jácome, Alexandre A., et al.
Publicado: (2023)

Clinical significance of neoadjuvant chemotherapy for locally advanced colorectal cancer patients with deficient mismatch repair: possibly residual value in the era of immunotherapy
por: Chen, Mian, et al.
Publicado: (2023)

Overexpression of MEKK2 is associated with colorectal carcinogenesis
por: JIANG, LI, et al.
Publicado: (2013)

Hsa-miR-19a is associated with lymph metastasis and mediates the TNF-α induced epithelial-to-mesenchymal transition in colorectal cancer
por: Huang, Lanlan, et al.
Publicado: (2015)

Elevated tumor-to-liver uptake ratio (TLR) from (18)F–FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection
por: Huang, Jun, et al.
Publicado: (2017)

Molecular Typing and Clinical Characteristics of Synchronous Multiple Primary Colorectal Cancer
por: Zhao, Yandong, et al.
Publicado: (2022)

Immunotherapy, Inflammation and Colorectal Cancer
por: Lichtenstern, Charles Robert, et al.
Publicado: (2020)

Exploring immunotherapy in colorectal cancer
por: Weng, Junyong, et al.
Publicado: (2022)

Gliotoxin Inhibits Proliferation and Induces Apoptosis in Colorectal Cancer Cells
por: Chen, Junxiong, et al.
Publicado: (2015)

The Immunotherapy for Colorectal Cancer, Lung Cancer and Pancreatic Cancer
por: Chen, Shiu-Jau, et al.
Publicado: (2021)

Relationship between serum lipid level and colorectal cancer: a systemic review and meta-analysis
por: Yang, Zhenpeng, et al.
Publicado: (2022)

Measurement of serum antibodies against NY-ESO-1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer
por: LONG, YAN-YAN, et al.
Publicado: (2014)

Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges
por: Wen, Xiaofen, et al.
Publicado: (2023)

Expert opinions on immunotherapy for patients with colorectal cancer
por: Wang, Feng, et al.
Publicado: (2020)

Nomograms for Prediction of Molecular Phenotypes in Colorectal Cancer
por: Yu, Zhuojun, et al.
Publicado: (2020)

Minimally Invasive Surgery for Colorectal Cancer
por: Yamauchi, Shinichi, et al.
Publicado: (2021)

PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
por: Song, Minmin, et al.
Publicado: (2013)

AQP9-induced cell cycle arrest is associated with RAS activation and improves chemotherapy treatment efficacy in colorectal cancer
por: Huang, Dandan, et al.
Publicado: (2017)

Immune checkpoints and immunotherapy for colorectal cancer
por: Singh, Preet Paul, et al.
Publicado: (2015)

Colorectal Cancer Immunotherapy: Options and Strategies
por: Johdi, Nor Adzimah, et al.
Publicado: (2020)

Combinatorial Immunotherapies for Metastatic Colorectal Cancer
por: Janssen, Eline, et al.
Publicado: (2020)

Perspectives on Immunotherapy of Metastatic Colorectal Cancer
por: Dai, Yongjiu, et al.
Publicado: (2021)

Emerging evidence of immunotherapy for colorectal cancer
por: Miyamoto, Yuji, et al.
Publicado: (2022)

Advances in minimally invasive neonatal colorectal surgery
por: Bandi, Ashwath S, et al.
Publicado: (2016)

MEK5 overexpression is associated with the occurrence and development of colorectal cancer
por: Diao, Dechang, et al.
Publicado: (2016)

Immunotherapy in colorectal cancer: current achievements and future perspective
por: Fan, Ahui, et al.
Publicado: (2021)

Tumor-Associated Neutrophils in Colorectal Cancer Development, Progression and Immunotherapy
por: Zheng, Wei, et al.
Publicado: (2022)

Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer
por: Karlsson, Mona, et al.
Publicado: (2010)

Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?
por: Sumransub, Nuttavut, et al.
Publicado: (2021)

Abnormal genetic and epigenetic patterns of m6A regulators associated with tumor microenvironment in colorectal cancer
por: Ren, Shuwei, et al.
Publicado: (2023)

Challenges and exploration for immunotherapies targeting cold colorectal cancer
por: Li, Dan-Dan, et al.
Publicado: (2023)

Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
por: Zheng, Yue, et al.
Publicado: (2022)

Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
por: Hu, Li-Feng, et al.
Publicado: (2021)

Ubiquitin ligase TRIM65 promotes colorectal cancer metastasis by targeting ARHGAP35 for protein degradation
por: Chen, Daici, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d4jbruuqk87k94jnq6u0gtru9t